Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease
| Autor: | Guilherme Trudes, Maria do Carmo Sampaio Tavares Timenetsky, Ivan França, Eloisa Bonfa, Rosa Maria Rodrigues Pereira, Clovis A. Silva, Vilma dos Santos Trindade Viana, Jozélio Freire de Carvalho, Alberto José da Silva Duarte, Nadia E. Aikawa, Carla G. S. Saad, Lucia M.A. Campos, João Luiz Miraglia |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Adolescent Immunology Population Arthritis Gastroenterology Young Adult Influenza A Virus H1N1 Subtype Rheumatology Rheumatic Diseases Internal medicine Influenza Human medicine Humans Immunology and Allergy Juvenile Prospective Studies Seroconversion Child education Glucocorticoids Juvenile dermatomyositis education.field_of_study business.industry medicine.disease Arthritis Juvenile Influenza Vaccines Vasculitis business Glucocorticoid medicine.drug |
| Zdroj: | The Journal of Rheumatology. 39:167-173 |
| ISSN: | 1499-2752 0315-162X |
| DOI: | 10.3899/jrheum.110721 |
| Popis: | Objective.To assess the immunogenicity and safety of non-adjuvanted influenza A H1N1/2009 vaccine in patients with juvenile autoimmune rheumatic disease (ARD) and healthy controls, because data are limited to the adult rheumatologic population.Methods.A total of 237 patients with juvenile ARD [juvenile systemic lupus erythematosus (JSLE), juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), juvenile scleroderma, and vasculitis] and 91 healthy controls were vaccinated. Serology for anti-H1N1 was performed by hemagglutination inhibition assay. Seroprotection rate, seroconversion rate, and factor-increase in geometric mean titer (GMT) were calculated. Adverse events were evaluated.Results.Age was comparable in patients and controls (14.8 ± 3.0 vs 14.6 ± 3.7 years, respectively; p = 0.47). Three weeks after immunization, seroprotection rate (81.4% vs 95.6%; p = 0.0007), seroconversion rate (74.3 vs 95.6%; p < 0.0001), and the factor-increase in GMT (12.9 vs 20.3; p = 0.012) were significantly lower in patients with juvenile ARD versus controls. Subgroup analysis revealed reduced seroconversion rates in JSLE (p < 0.0001), JIA (p = 0.008), JDM (p = 0.025), and vasculitis (p = 0.017). Seroprotection (p < 0.0001) and GMT (p < 0.0001) were decreased only in JSLE. Glucocorticoid use and lymphopenia were associated with lower seroconversion rates (60.4 vs 82.9%; p = 0.0001; and 55.6 vs 77.2%; p = 0.012). Multivariate logistic regression including diseases, lymphopenia, glucocorticoid, and immunosuppressants demonstrated that only glucocorticoid use (p = 0.012) remained significant.Conclusion.This is the largest study to demonstrate a reduced but adequate immune response to H1N1 vaccine in patients with juvenile ARD. It identified current glucocorticoid use as the major factor for decreased antibody production. The short-term safety results support its routine recommendation for patients with juvenile ARD. ClinicalTrials.gov; NCT01151644. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|